Trial Details
Relatlimab + Nivolumab + Ipilimumab
Area of Research: Advanced Solid Tumors
Phase 1/2

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Brief Summary:

The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

For more information, please contact the recruiting sites directly.
If there is no contact information, please email: The first line of the email MUST contain the NCT # and Site #.

24 locations available.

Log In

Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create Account

Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

  • 8 characters minimum
  • First character cannot be a number
  • Last character cannot be a number